Table 1.
Demographic Characteristics of the 15 Study Patients
| Overall Cohortc | |
|---|---|
| Age, median (IQR), y | 51 (42-55) |
| Female gender | 10 (66.7) |
| Ethnicity | |
| White | 11 (73.3) |
| African American | 2 (13.3) |
| Asian | 2 (13.3) |
| Primary cause of ESRD | |
| Diabetes mellitus | 1 (6.7) |
| Cystic disease | 5 (33.3) |
| Glomerulonephritis | 4 (26.7) |
| Unknown | 1 (6.7) |
| Others | 4 (26.7) |
| Type of donor | |
| Living | 8 (53.3) |
| Deceased | 7 (46.7) |
| BMI, median (IQR), kg/m2 | 29.4 (26.2-36.5) |
| Blood group | |
| O | 4 (26.7) |
| A | 9 (60.0) |
| B | 1 (6.7) |
| AB | 1 (6.7) |
| Baseline detectable DSA (any MFI) | 12 (80.0) |
| Baseline positive B flow cytometric XM | 6 (40.0) |
| Baseline channel shift among +XM, median (IQR) (n = 6) | |
| B | 149.5 (113.3-187.5) |
| T | 89 (48.25-128.5) |
| Baseline sum MFI of DSA procedures among +XM, median (IQR) (n = 6) | |
| Class I | 1507 (0-2727) |
| Class II | 0 (0-2347.5) |
| Receiving dialysis at time of transplant | 9 (60.0) |
| cPRA, median (IQR) | 93 (0-99) |
| Prior pregnancy (n = 10) | 8 (80.0) |
| Retransplant | 7 (46.7) |
| HLA mismatches, median (IQR) | |
| A, B, DR | 4 (3-5) |
| Class II DR, DP | 2 (1-4) |
| Preconditioning with rituximab and plasmapheresis | 1 (6.7) |
| Type of induction | |
| Thymoglobulin | 10 (66.7) |
| Alemtuzumab | 5 (33.3) |
| Initial maintenance immunosuppression | |
| Tacrolimus, mycophenolate mofetil, prednisone | 10 (66.7) |
| Tacrolimus, mycophenolate mofetil | 5 (33.3) |
| Delayed graft function | 3 (20.0) |
| Follow-up, median (IQR), months | 13(12-19) |
Abbreviations: BMI, body mass index; cPRA, calculated panel-reactive antibody; DSA, donor-specific antibody; ESRD, end-stage renal disease; IQR, interquartile range; MFI, mean fluorescence intensity; XM, crossmatch; +XM, positive crossmatch.
a
Values are presented as number and percentage of patients unless specified otherwise.